Literature DB >> 29701247

Does perinatal exposure to exogenous oxytocin influence child behavioural problems and autistic-like behaviours to 20 years of age?

Adam J Guastella1, Matt N Cooper2, Christopher R H White3, Melanie K White3, Craig E Pennell3, Andrew J O Whitehouse2.   

Abstract

BACKGROUND: The neuropeptide and hormone oxytocin is known to have a significant impact on social cognition and behaviour in humans. There is growing concern regarding the influence of exogenous oxytocin (OT) administration in early life on later social and emotional development, including autism spectrum disorder (ASD). No study has examined offspring development in relation to the dose of exogenous oxytocin administered during labour.
METHODS: Between 1989 and 1992, 2,900 mothers were recruited prior to the 18th week of pregnancy, delivering 2,868 live offspring. The Child Behaviour Checklist was used to measure offspring behavioural difficulties at ages 5, 8, 10, 14 and 17 years. Autism spectrum disorder was formally diagnosed by consensus of a team of specialists. At 20 years, offspring completed a measure of autistic-like traits, the Autism Spectrum Quotient (AQ). Oxytocin exposure prior to birth was analysed using categorical and continuous approaches (maternal oxytocin dose) with univariate and multivariate statistical techniques.
RESULTS: Categorical analyses of oxytocin exposure prior to birth demonstrated no group differences in any measures of child behaviour. A small in magnitude dose-response association was observed for clinically significant total behaviour symptoms (adjusted odds ratio 1.03; 95% CI: 1.01-1.06, p < .01). Exogenous oxytocin administration prior to birth was not associated with ASD (OR: 0.64; 95% CI: 0.15-2.12, p = .46) or high levels of autistic-like traits (p = .93), as assessed by the AQ.
CONCLUSIONS: This study is the first to investigate longitudinal mental health outcomes associated with the use of oxytocin-based medications during labour. The results do not provide evidence to support the theory that exogenous OT has a clinically significant negative impact on the long-term mental health of children.
© 2018 Association for Child and Adolescent Mental Health.

Entities:  

Keywords:  Autism spectrum disorders; behaviour problems; developmental psychopathology; empathy; public health

Mesh:

Substances:

Year:  2018        PMID: 29701247     DOI: 10.1111/jcpp.12924

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  4 in total

1.  Behavioral and epigenetic consequences of oxytocin treatment at birth.

Authors:  W M Kenkel; A-M Perkeybile; J R Yee; H Pournajafi-Nazarloo; T S Lillard; E F Ferguson; K L Wroblewski; C F Ferris; C S Carter; J J Connelly
Journal:  Sci Adv       Date:  2019-05-01       Impact factor: 14.136

2.  Labor induction with oxytocin in pregnant rats is not associated with oxidative stress in the fetal brain.

Authors:  Tusar Giri; Jia Jiang; Zhiqiang Xu; Ronald McCarthy; Carmen M Halabi; Eric Tycksen; Alison G Cahill; Sarah K England; Arvind Palanisamy
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

3.  Birth Weight and Childhood Psychopathology in the ABCD Cohort: Association is Strongest for Attention Problems and is Moderated by Sex.

Authors:  Niamh Dooley; Mary Clarke; David Cotter; Mary Cannon
Journal:  Res Child Adolesc Psychopathol       Date:  2022-01-24

Review 4.  Oxytocin Dynamics in the Body and Brain Regulated by the Receptor for Advanced Glycation End-Products, CD38, CD157, and Nicotinamide Riboside.

Authors:  Haruhiro Higashida; Kazumi Furuhara; Olga Lopatina; Maria Gerasimenko; Osamu Hori; Tsuyoshi Hattori; Yasuhiko Hayashi; Stanislav M Cherepanov; Anna A Shabalova; Alla B Salmina; Kana Minami; Teruko Yuhi; Chiharu Tsuji; PinYue Fu; Zhongyu Liu; Shuxin Luo; Anpei Zhang; Shigeru Yokoyama; Satoshi Shuto; Mizuki Watanabe; Koichi Fujiwara; Sei-Ichi Munesue; Ai Harashima; Yasuhiko Yamamoto
Journal:  Front Neurosci       Date:  2022-07-07       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.